DrugPatentWatch Database Preview
Pazopanib hydrochloride - Generic Drug Details
What are the generic drug sources for pazopanib hydrochloride and what is the scope of patent protection?
Pazopanib hydrochloride
is the generic ingredient in one branded drug marketed by Novartis and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.Pazopanib hydrochloride has forty patent family members in twenty-five countries.
There are five drug master file entries for pazopanib hydrochloride. One supplier is listed for this compound.
Summary for pazopanib hydrochloride
| International Patents: | 40 |
| US Patents: | 3 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Drug Master File Entries: | 5 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 84 |
| Clinical Trials: | 270 |
| Patent Applications: | 102 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | pazopanib hydrochloride at DailyMed |
Recent Clinical Trials for pazopanib hydrochloride
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Cure HHT | Phase 1/Phase 2 |
| Cure HHT | Phase 2/Phase 3 |
| University of North Carolina | Phase 1/Phase 2 |
Pharmacology for pazopanib hydrochloride
| Drug Class | Kinase Inhibitor |
| Mechanism of Action | Protein Kinase Inhibitors Cytochrome P450 3A4 Inhibitors Cytochrome P450 2D6 Inhibitors Cytochrome P450 2C8 Inhibitors |
Synonyms for pazopanib hydrochloride
| 33Y9ANM545 |
| 5-((4-((2,3-DIMETHYL-2H-INDAZOL-6-YL)(METHYL)AMINO)PYRIMIDIN-2-YL)AMINO)-2-METHYLBENZENESULFONAMIDE HYDROCHLORIDE |
| 5-((4-((2,3-Dimethyl-2H-indazol-6-yl)methylamino)pyrimidin-2-yl)amino)-2-methylbenzenesulfonamide monohydrochloride |
| 5-({4-[(2,3-dimethyl-2H-indazol-6-yl)(methyl)amino]-2-pyrimidinyl}amino)-2-methylbenzenesulfonamide Hydrochloride |
| 5-({4-[(2,3-dimethyl-2H-indazol-6-yl)(methyl)amino]pyrimidin-2-yl}amino)-2-methylbenzenesulfonamide hydrochloride |
| 5-({4-[(2,3-dimethylindazol-6-yl)(methyl)amino]pyrimidin-2-yl}amino)-2-methylbenzenesulfonamide hydrochloride |
| 5-(4-((2,3-dimethyl-2H-indazol-6-yl)(methyl)amino)pyrimidin-2-ylamino)-2-methylbenzenesulfonamide hydrochloride |
| 5-[[4-[(2,3-dimethyl-6-indazolyl)-methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide hydrochloride |
| 5-[[4-[(2,3-dimethylindazol-6-yl)-methyl-amino]pyrimidin-2-yl]amino]-2-methyl-benzenesulfonamide hydrochloride |
| 635702-64-6 |
| A834417 |
| AC-24726 |
| AK163181 |
| AKOS015958593 |
| AM20090655 |
| AN-16933 |
| Armala |
| AX8294838 |
| BCP02203 |
| BCP9001052 |
| Benzenesulfonamide, 5-((4-((2,3-dimethyl-2H-indazol-6-yl)methylamino)-2-pyrimidinyl)amino)-2-methyl-, monohydrochloride |
| Benzenesulfonamide, 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-, hydrochloride (1:1) |
| C21H23N7O2S.HCl |
| CHEBI:71217 |
| CHEMBL1201733 |
| CS-0126 |
| D05380 |
| DTXSID70212956 |
| EX-A956 |
| FT-0687642 |
| GSK-786034 |
| GW 786034 |
| GW-786034B |
| GW786034 |
| GW786034 HCl |
| GW786034B |
| GW786034GW786034 |
| HY-12009 |
| KB-79770 |
| KS-000003E0 |
| KS-1458 |
| MLS004774147 |
| MolPort-009-679-403 |
| MQHIQUBXFFAOMK-UHFFFAOYSA-N |
| NSC-737754 |
| NSC737754 |
| Patorma |
| Pazopanib (Hydrochloride) |
| pazopanib HCl |
| Pazopanib HCl (GW786034 ) |
| Pazopanib HCl (GW786034 HCl) |
| Pazopanib hydrochloride (JAN/USAN) |
| Pazopanib hydrochloride [USAN:JAN] |
| pazopanib monohydrochloride |
| PB31655 |
| S1035 |
| SB10367 |
| SC-90768 |
| SCHEMBL159487 |
| SMR003500790 |
| ST24048877 |
| SW218082-2 |
| SYN1058A |
| UNII-33Y9ANM545 |
| Votrient |
| Votrient (TN) |
| W-5532 |
| X3177 |
US Patents and Regulatory Information for pazopanib hydrochloride
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | VOTRIENT | pazopanib hydrochloride | TABLET;ORAL | 022465-001 | Oct 19, 2009 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Novartis | VOTRIENT | pazopanib hydrochloride | TABLET;ORAL | 022465-002 | Oct 19, 2009 | DISCN | No | No | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Novartis | VOTRIENT | pazopanib hydrochloride | TABLET;ORAL | 022465-001 | Oct 19, 2009 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Novartis | VOTRIENT | pazopanib hydrochloride | TABLET;ORAL | 022465-002 | Oct 19, 2009 | DISCN | No | No | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Novartis | VOTRIENT | pazopanib hydrochloride | TABLET;ORAL | 022465-001 | Oct 19, 2009 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for pazopanib hydrochloride
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Hong Kong | 1149930 | Start Trial |
| European Patent Office | 2311825 | Start Trial |
| Poland | 214667 | Start Trial |
| Hungary | S1700003 | Start Trial |
| Australia | 2002246723 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for pazopanib hydrochloride
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1343782 | CA 2010 00024 | Denmark | Start Trial | PRODUCT NAME: PAZOPANIB, EVENTUELT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT ELLER SOLVAT DERAF, HERUNDER HYDROCLORID |
| 1343782 | SPC/GB10/032 | United Kingdom | Start Trial | PRODUCT NAME: PAZOPANIB, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE; REGISTERED: UK EU 1/10/628/001 20100614; UK EU 1/10/628/002 20100614; UK EU 1/10/628/003 20100614; UK EU 1/10/628/004 20100614 |
| 1343782 | 91710 | Luxembourg | Start Trial | 91710, EXPIRES: 20250614 |
| 1343782 | C01343782/01 | Switzerland | Start Trial | FORMER OWNER: GLAXOSMITHKLINE LLC, US |
| 1343782 | 28/2010 | Austria | Start Trial | PRODUCT NAME: PAZOPANIB, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES ODER SOLVATS DAVON; REGISTRATION NO/DATE: EU/1/10/628/001 - EU/1/10/628/004 20100614 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright 2002-2019 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2019 - 2020
NCE-1 Patent Challenge Dates 2019 - 2020
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2019 - 2020
NCE-1 Patent Challenge Dates 2019 - 2020
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2019, www.DrugPatentWatch.com.